4 Healthcare Stock Stories Making Tracks on Monday
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS): Closing price $31.81
On Monday, Biogen IDEC and Isis announced that they will work jointly to leverage antisense tech in the advancement of the treatment of neurological diseases. The accord unites Biogen Idec’s expertise in neurology with Isis’ leadership in antisense tech to develop novel therapies through which to treat neurological disorders. This marks the fourth collaboration between the firms in the last two years. As part of the six-year research collaboration, Biogen Idec will obtain exclusive rights to the use of Isis’ antisense tech to develop therapies for neurological diseases.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.